tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
PremiumRatingsPromising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment
2M ago
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
Premium
Ratings
Cautious Hold Rating for Nektar Therapeutics Amid Mixed Rezpeg Trial Results
2M ago
Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
Premium
Ratings
Positive Outlook for Nektar Therapeutics Amid Promising Rezpeg Trial Results and Increased Price Target
2M ago
Nektar to hold conference call on Phase 2b Rezpegaldesleukin results
PremiumThe FlyNektar to hold conference call on Phase 2b Rezpegaldesleukin results
2M ago
Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
Premium
Weekend Updates
Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts
2M ago
Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls
Premium
The Fly
Autodesk upgraded, Nio downgraded: Wall Street’s top analyst calls
2M ago
Nektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment
PremiumRatingsNektar Therapeutics: Buy Rating Driven by Promising REZPEG Data and Favorable Safety Profile in Alopecia Areata Treatment
3M ago
Nektar files automatic mixed securities shelf
Premium
The Fly
Nektar files automatic mixed securities shelf
3M ago
Nektar Therapeutics Reveals Promising Phase 2b Trial Results
Premium
Company Announcements
Nektar Therapeutics Reveals Promising Phase 2b Trial Results
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100